ReviewPaediatric drugs2008
Treatment of invasive candidiasis in immunocompromised pediatric patients.
Review in Paediatric drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.Journal of cancer research and clinical oncology · 2017Trial
- Effect of biogenic selenium nanoparticles on ERG11 and CDR1 gene expression in both fluconazole-resistant and -susceptibleCurrent medical mycology · 2017Article
- Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.BMC infectious diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the last 3 decades, systemic candidiasis has become increasingly recognized as a major source of morbidity and mortality in immunocompromised pediatric patients. As the number of children receiving chemotherapy and bone marrow transplantations continue to increase, clinicians should expect that invasive infections from Candida spp. will also increase in these vulnerable hosts. Fortunately, in the past 15 years, the evolution of older antifungals coupled with the discovery of new classes of antifungal agents has equipped physicians with reasonable options for treating these otherwise life-threatening infections.This review aims to familiarize the reader with the evolving epidemiology of candidiasis in immunocompromised children as well as discuss therapeutic options from each class of antifungal agents. Mechanisms of action, pharmacokinetics, toxicities, resistance patterns, chemotherapy interactions, and clinical relevance in immunocompromised children are reviewed for polyenes, flucytosine (5-fluorocytosine), azoles, and echinocandins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.